Gabapentin: A Non-Hormonal Option for the Treatment of Menopausal Vasomotor Symptoms
Current guidelines list gabapentin as a recommended nonhormonal therapy for vasomotor symptoms in women who cannot or prefer not to use hormone therapy.
Clinical Update 2025: Recommendations on the Use of Antidepressants in Women Taking Tamoxifen
While some antidepressants may affect the metabolism of tamoxifen into its active form, many antidepressants can be used safely in this population.
True or False: Myths and Misconceptions About Bioidentical Hormones for Menopausal Symptoms
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
CBT and Mindfulness-Based Interventions for the Treatment of Anxiety and Depression in Perimenopausal Women
This review and meta-analysis reviews the effectiveness of cognitive behavioral therapy and mindfulness interventions for depression, anxiety, and cognitive functioning in women undergoing menopausal transition. Â
Recruiting for Research Study: Pregnenolone Neurosteroid for Menopausal Depression
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
Menopause Increases Risk of Relapse in Women with Schizophrenia
Menopause is a period of increased risk for women with schizophrenia spectrum disorders, and women are at higher risk for relapse than their age-matched male counterparts.
Essential Reads: What You Need to Know About Bioidentical Hormone Therapy for Menopausal Symptoms
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
FDA Accepts New Drug Application for Fezolinetant, A Novel Nonhormonal Treatment for Vasomotor Symptoms
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
New Research Study at the CWMH: A Novel Treatment for Menopausal Depression
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Essential Reads: Who is at Risk for Depression During the Perimenopause?
Although most women transition to menopause without experiencing psychiatric problems, an estimated 20% experience depression at some point during the menopausal transition.